{"transactions":[{"id":691718,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to buy)","published_at":"2026-08-10T20:08:41.000Z","date":"2026-08-06","kind":"exercise","planned":false,"acquired":false,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted by the Issuer on January 31, 2023 and vest over four years: 25% of the options vested on January 31, 2024 with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":525000,"derivative":{"exercise_price":0.63,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001591467-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000159146726000004/primarydocument.xml","form_type":"4"}},{"id":691717,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-08-10T20:08:41.000Z","date":"2026-08-06","kind":"exercise","planned":false,"acquired":true,"shares":350000,"price":0.63,"value":220500.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2026 under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan."}],"balance_after":3718564,"source":{"system":"sec-edgar","filing":"0001591467-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000159146726000004/primarydocument.xml","form_type":"4"}},{"id":857987,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-03-05T23:55:46.000Z","date":"2026-03-04","kind":"purchase","planned":false,"acquired":true,"shares":69270,"price":1.25,"value":86587.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person's purchase of Akebia Therapeutics, Inc. (\"Akebia\") common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 69,270 shares, with the reporting person's sale of 341,305 shares of Akebia common stock at a price of $1.39 per share on February 2, 2026 pursuant to an automatic sell-to-cover instruction solely to cover applicable withholding taxes in connection with the vesting of the reporting person's RSUs granted on January 31, 2023, 2024 and 2025. The reporting person has paid Akebia, upon settlement of the sale, $9,664.60 representing the full amount of the profit realized in connection with the short-swing transaction."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.23 to $1.28, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."}],"balance_after":3367064,"source":{"system":"sec-edgar","filing":"0001591467-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000159146726000003/primarydocument.xml","form_type":"4"}},{"id":919122,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-02-04T21:10:28.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":83689,"price":1.39,"value":116327.71,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025."},{"field":"shares","element":"transactionShares","label":"F6","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's performance stock units granted on January 31, 2025."}],"balance_after":3297794,"source":{"system":"sec-edgar","filing":"0001591467-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000159146726000002/primarydocument.xml","form_type":"4"}},{"id":919121,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-02-04T21:10:28.000Z","date":"2026-02-02","kind":"grant","planned":true,"acquired":true,"shares":175250,"price":1.41,"value":247102.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"As reported in February 2025, the Reporting Person was granted performance-based restricted stock units (\"PSUs\") pursuant to the Issuer's 2023 Stock Incentive Plan, as amended.  Each PSU right represents a contingent right to receive one share of the Issuer's common stock. One-half of the total number of shares of common stock underlying the PSUs vests on the later of (i) the first anniversary of the grant date and (ii) the date that the Compensation Committee certifies that the average closing price of the Issuer's common stock equals or exceeds $3.50 over a 30-day trading period (the \"Stock Price Hurdle 1 Performance Condition\"),  subject to the reporting persons continuous employment through the applicable vesting date.  In July2025, the Compensation Committee certified that the Stock Price Hurdle 1 Performance Condition was met during the performance period and therefore one-half of the PSUs vested on January 31, 2026."}],"balance_after":3381483,"source":{"system":"sec-edgar","filing":"0001591467-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000159146726000002/primarydocument.xml","form_type":"4"}},{"id":919120,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-02-04T21:10:28.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":114891,"price":1.39,"value":159698.49,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025."},{"field":"shares","element":"transactionShares","label":"F4","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025."}],"balance_after":3206233,"source":{"system":"sec-edgar","filing":"0001591467-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000159146726000002/primarydocument.xml","form_type":"4"}},{"id":919119,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-02-04T21:10:28.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":96065,"price":1.39,"value":133530.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025."},{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024."}],"balance_after":3321124,"source":{"system":"sec-edgar","filing":"0001591467-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000159146726000002/primarydocument.xml","form_type":"4"}},{"id":919118,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-02-04T21:10:28.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":46660,"price":1.39,"value":64857.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2023."},{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025."}],"balance_after":3417189,"source":{"system":"sec-edgar","filing":"0001591467-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000159146726000002/primarydocument.xml","form_type":"4"}},{"id":921233,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to buy)","published_at":"2026-02-03T21:35:35.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":1115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":1115000,"derivative":{"exercise_price":1.41,"expiration_date":"2036-01-30","underlying":"Common Stock","underlying_shares":1115000},"source":{"system":"sec-edgar","filing":"0001591467-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000159146726000001/primarydocument.xml","form_type":"4"}},{"id":921232,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-02-03T21:35:35.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":743000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended.   One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 159,928 shares previously held by John Butler 2019 GRAT, and 1,500 shares of the Issuer's common stock purchased on June 30, 2025 and 1,500 shares of the Issuer's common stock purchased on December 31, 2025, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan."}],"balance_after":3463849,"source":{"system":"sec-edgar","filing":"0001591467-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000159146726000001/primarydocument.xml","form_type":"4"}},{"id":1226889,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2025-03-04T22:05:06.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":46409,"price":1.83,"value":84928.47,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022."},{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2023."}],"balance_after":2557921,"source":{"system":"sec-edgar","filing":"0001562180-25-001998","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218025001998/primarydocument.xml","form_type":"4"}},{"id":1283965,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to buy)","published_at":"2025-02-04T22:54:18.000Z","date":"2025-01-31","kind":"grant","planned":true,"acquired":true,"shares":1051400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":1051400,"derivative":{"exercise_price":2.24,"expiration_date":"2035-01-31","underlying":"Common Stock","underlying_shares":1051400},"source":{"system":"sec-edgar","filing":"0001562180-25-000917","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218025000917/primarydocument.xml","form_type":"4"}},{"id":1283964,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Performance Stock Units","published_at":"2025-02-04T22:54:18.000Z","date":"2025-01-31","kind":"grant","planned":true,"acquired":true,"shares":350500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Performance Stock Unit (\"PSU\") right represents a contingent right to receive one share of the Issuer's common stock. One-half of the total number of shares of common stock underlying the PSUs shall vest on each of (a) the later of (i) the first anniversary of the grant date and (ii) the date that the Compensation Committee certifies that the average closing price of the Issuer's common stock equals or exceeds $3.50 over a 30-day trading period, and (b) the later of (i) the first anniversary of the grant date and (ii) the date that the Compensation Committee certifies that the average closing price of the Issuer's common stock equals or exceeds $5.00 for over a 30-day trading period, subject to the reporting person's continued service with the Issuer through the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each Performance Stock Unit (\"PSU\") right represents a contingent right to receive one share of the Issuer's common stock. One-half of the total number of shares of common stock underlying the PSUs shall vest on each of (a) the later of (i) the first anniversary of the grant date and (ii) the date that the Compensation Committee certifies that the average closing price of the Issuer's common stock equals or exceeds $3.50 over a 30-day trading period, and (b) the later of (i) the first anniversary of the grant date and (ii) the date that the Compensation Committee certifies that the average closing price of the Issuer's common stock equals or exceeds $5.00 for over a 30-day trading period, subject to the reporting person's continued service with the Issuer through the applicable vesting date."}],"balance_after":350500,"derivative":{"expiration_date":"2027-01-31","underlying":"Common Stock","underlying_shares":350500},"source":{"system":"sec-edgar","filing":"0001562180-25-000917","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218025000917/primarydocument.xml","form_type":"4"}},{"id":1283963,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2025-02-04T22:54:18.000Z","date":"2025-02-03","kind":"sale","planned":true,"acquired":false,"shares":97982,"price":2.1,"value":205762.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2023."},{"field":"shares","element":"transactionShares","label":"F5","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024."}],"balance_after":2604330,"source":{"system":"sec-edgar","filing":"0001562180-25-000917","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218025000917/primarydocument.xml","form_type":"4"}},{"id":1283962,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2025-02-04T22:54:18.000Z","date":"2025-02-03","kind":"sale","planned":true,"acquired":false,"shares":46268,"price":2.1,"value":97162.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2023."},{"field":"shares","element":"transactionShares","label":"F4","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2023."}],"balance_after":2702312,"source":{"system":"sec-edgar","filing":"0001562180-25-000917","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218025000917/primarydocument.xml","form_type":"4"}},{"id":1283961,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2025-02-04T22:54:18.000Z","date":"2025-01-31","kind":"grant","planned":true,"acquired":true,"shares":701000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan.   One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,500 shares of the Issuer's common stock purchased on June 28, 2024  and 1,500 shares of the Issuer's common stock purchased on December 31, 2024, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan."}],"balance_after":2748580,"source":{"system":"sec-edgar","filing":"0001562180-25-000917","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218025000917/primarydocument.xml","form_type":"4"}},{"id":1606386,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2024-03-01T22:47:34.000Z","date":"2024-02-29","kind":"sale","planned":false,"acquired":false,"shares":46570,"price":1.58,"value":73580.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022."}],"balance_after":2044580,"source":{"system":"sec-edgar","filing":"0001562180-24-002021","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218024002021/primarydocument.xml","form_type":"4"}},{"id":1609561,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2024-02-29T23:00:49.000Z","date":"2024-02-27","kind":"sale","planned":false,"acquired":false,"shares":37733,"price":1.52,"value":57354.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021."}],"balance_after":2091150,"source":{"system":"sec-edgar","filing":"0001562180-24-001992","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218024001992/primarydocument.xml","form_type":"4"}},{"id":1660932,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to buy)","published_at":"2024-02-02T21:10:30.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":905200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":905200,"derivative":{"exercise_price":1.68,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":905200},"source":{"system":"sec-edgar","filing":"0001562180-24-000971","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218024000971/primarydocument.xml","form_type":"4"}},{"id":1660931,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2024-02-02T21:10:30.000Z","date":"2024-02-01","kind":"sale","planned":false,"acquired":false,"shares":46489,"price":1.68,"value":78101.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31,2023."}],"balance_after":2128883,"source":{"system":"sec-edgar","filing":"0001562180-24-000971","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218024000971/primarydocument.xml","form_type":"4"}},{"id":1660930,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2024-02-02T21:10:30.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":603500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan.   One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2023 and 1,500 shares of the Issuer's common stock purchased on December 29, 2023, each under the Issuer's  Amended and Restated 2014 Employee Stock Purchase Plan."}],"balance_after":2175372,"source":{"system":"sec-edgar","filing":"0001562180-24-000971","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218024000971/primarydocument.xml","form_type":"4"}},{"id":1761654,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-11T13:58:51.000Z","date":"2023-10-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":71736,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5)"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment."}],"balance_after":0,"derivative":{"exercise_price":0.3501,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":71736},"source":{"system":"sec-edgar","filing":"0001140361-23-047727","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1591467/000114036123047727/form4.xml","form_type":"4"}},{"id":1761653,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-11T13:58:51.000Z","date":"2023-10-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34663,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5)"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment."}],"balance_after":0,"derivative":{"exercise_price":1.01,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":34663},"source":{"system":"sec-edgar","filing":"0001140361-23-047727","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1591467/000114036123047727/form4.xml","form_type":"4"}},{"id":1761652,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-10-11T13:58:51.000Z","date":"2023-10-10","kind":"other","planned":false,"acquired":false,"shares":47824,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This line item represents unvested restricted stock awards (\"RSAs\") with performance-based vesting previously granted to the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This line item represents unvested restricted stock awards (\"RSAs\") with performance-based vesting previously granted to the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-23-047727","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1591467/000114036123047727/form4.xml","form_type":"4"}},{"id":1761651,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-10-11T13:58:51.000Z","date":"2023-10-10","kind":"other","planned":false,"acquired":false,"shares":32941,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 14, 2023, by and among the Issuer, Harmony Biosciences Holdings, Inc., a Delaware corporation (\"Parent\") and Xylophone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub completed a tender offer (the \"Offer\") for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, effective as of October 10, 2023 (the \"Effective Time\" with the Issuer surviving the merger). (continued in footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $1.1059 per Share (the \"Cash Amount\") in cash, subject to any applicable withholding taxes and without interest, plus (b) one contingent value right (each, a \"CVR\") per Share (the \"CVR Amount\" and together with the Cash Amount, the \"Merger Consideration\"), which represents the right to receive up to approximately $2.5444 per Share in the form of one or more potential contingent payments, in cash, subject to any applicable withholding taxes and without interest, upon the achievement of certain milestones (such applicable payment, each, a \"Milestone Payment\")."}],"balance_after":47824,"source":{"system":"sec-edgar","filing":"0001140361-23-047727","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591467/000114036123047727/form4.xml","form_type":"4"}},{"id":1853854,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-15T20:28:56.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":71736,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in full upon the earlier of (i) June 13, 2024 or (ii) the day before the Company's 2024 annual meeting of stockholders."}],"balance_after":71736,"derivative":{"exercise_price":0.3501,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":71736},"source":{"system":"sec-edgar","filing":"0001062993-23-013664","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1591467/000106299323013664/form4.xml","form_type":"4"}},{"id":1853853,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-15T20:28:56.000Z","date":"2023-06-14","kind":"sale","planned":false,"acquired":false,"shares":115,"price":0.3481,"value":40.0315,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This transaction represents shares required to be sold by the Reporting Person to satisfy certain equity plan administrator fees and taxes in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person."}],"balance_after":80765,"source":{"system":"sec-edgar","filing":"0001062993-23-013664","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1591467/000106299323013664/form4.xml","form_type":"4"}},{"id":1853852,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-15T20:28:56.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":47824,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock award vests in full upon the earlier of (i) June 13, 2024 or (ii) the day before the Company's 2024 annual meeting of stockholders."}],"balance_after":80880,"source":{"system":"sec-edgar","filing":"0001062993-23-013664","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591467/000106299323013664/form4.xml","form_type":"4"}},{"id":1971974,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-03-03T13:01:34.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":6370,"price":0.8775,"value":5589.675,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021."}],"balance_after":1568872,"source":{"system":"sec-edgar","filing":"0001562180-23-002201","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218023002201/primarydocument.xml","form_type":"4"}},{"id":1971973,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-03-03T13:01:34.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":47239,"price":0.8775,"value":41452.2225,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022."}],"balance_after":1575242,"source":{"system":"sec-edgar","filing":"0001562180-23-002201","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218023002201/primarydocument.xml","form_type":"4"}},{"id":1971972,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-03-03T13:01:34.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":38259,"price":0.8775,"value":33572.2725,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020."}],"balance_after":1622481,"source":{"system":"sec-edgar","filing":"0001562180-23-002201","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218023002201/primarydocument.xml","form_type":"4"}},{"id":1983109,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-03-01T21:07:05.000Z","date":"2023-02-27","kind":"sale","acquired":false,"shares":38632,"price":0.8132,"value":31415.5424,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021."}],"balance_after":1660740,"source":{"system":"sec-edgar","filing":"0001562180-23-002041","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218023002041/primarydocument.xml","form_type":"4"}},{"id":2035285,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to buy)","published_at":"2023-02-02T21:15:15.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":875000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":875000,"derivative":{"exercise_price":0.63,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":875000},"source":{"system":"sec-edgar","filing":"0001562180-23-000832","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218023000832/primarydocument.xml","form_type":"4"}},{"id":2035284,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Appreciation Right","published_at":"2023-02-02T21:15:15.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":635313,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock appreciation rights (\"SARs\") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The SARs will vest over four years: 25% of the SARs will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":635313,"derivative":{"exercise_price":0.63,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":635313},"source":{"system":"sec-edgar","filing":"0001562180-23-000832","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218023000832/primarydocument.xml","form_type":"4"}},{"id":2035283,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-02-02T21:15:15.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":293125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2022 and 1,500 shares of the Issuer's common stock purchased on December 30, 2022, each under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan."}],"balance_after":1699372,"source":{"system":"sec-edgar","filing":"0001562180-23-000832","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218023000832/primarydocument.xml","form_type":"4"}},{"id":2229503,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T01:48:27.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":34663,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in full upon the earlier of (i) June 14, 2023 or (ii) the day before the Company's 2023 annual meeting of stockholders."}],"balance_after":34663,"derivative":{"exercise_price":1.01,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":34663},"source":{"system":"sec-edgar","filing":"0001062993-22-015037","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1591467/000106299322015037/form4.xml","form_type":"4"}},{"id":2229502,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-17T01:48:27.000Z","date":"2022-06-14","kind":"sale","acquired":false,"shares":53,"price":1.01,"value":53.53,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This transaction represents shares required to be sold by the Reporting Person to satisfy certain equity plan administrator fees and taxes in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person."}],"balance_after":33056,"source":{"system":"sec-edgar","filing":"0001062993-22-015037","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1591467/000106299322015037/form4.xml","form_type":"4"}},{"id":2229501,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-17T01:48:27.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":23109,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock award vests in full upon the earlier of (i) June 14, 2023 or (ii) the day before the Company's 2023 annual meeting of stockholders."}],"balance_after":33109,"source":{"system":"sec-edgar","filing":"0001062993-22-015037","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591467/000106299322015037/form4.xml","form_type":"4"}},{"id":2359638,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2022-03-03T02:25:01.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":739700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":739700,"derivative":{"exercise_price":2.16,"expiration_date":"2032-02-28","underlying":"Common Stock","underlying_shares":739700},"source":{"system":"sec-edgar","filing":"0001562180-22-002166","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218022002166/primarydocument.xml","form_type":"4"}},{"id":2359637,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2022-03-03T02:25:01.000Z","date":"2022-03-01","kind":"sale","acquired":false,"shares":4131,"price":2.1707,"value":8967.1617,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021."}],"balance_after":1403247,"source":{"system":"sec-edgar","filing":"0001562180-22-002166","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218022002166/primarydocument.xml","form_type":"4"}},{"id":2359636,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2022-03-03T02:25:01.000Z","date":"2022-03-01","kind":"sale","acquired":false,"shares":25031,"price":2.1707,"value":54334.7917,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019."}],"balance_after":1407378,"source":{"system":"sec-edgar","filing":"0001562180-22-002166","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218022002166/primarydocument.xml","form_type":"4"}},{"id":2359635,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2022-03-03T02:25:01.000Z","date":"2022-03-01","kind":"sale","acquired":false,"shares":24811,"price":2.1707,"value":53857.2377,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020."}],"balance_after":1432409,"source":{"system":"sec-edgar","filing":"0001562180-22-002166","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218022002166/primarydocument.xml","form_type":"4"}},{"id":2359634,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2022-03-03T02:25:01.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":293125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One-third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":1457220,"source":{"system":"sec-edgar","filing":"0001562180-22-002166","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218022002166/primarydocument.xml","form_type":"4"}},{"id":2359633,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2022-03-03T02:25:01.000Z","date":"2022-02-28","kind":"sale","acquired":false,"shares":25053,"price":2.1548,"value":53984.2044,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (i) the 1,248 shares of common stock that were described in the amendment on Form 4/A filed by the reporting person with the SEC on February 18, 2022, (ii) 1,500 shares of the Issuer's common stock purchased on each of June 30, 2021 and December 31, 2021, each under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan, and (iii) 32,747 shares of common stock that represent a change from indirect to direct ownership of shares previously reported as beneficially owned by the reporting person."}],"balance_after":1164095,"source":{"system":"sec-edgar","filing":"0001562180-22-002166","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218022002166/primarydocument.xml","form_type":"4"}},{"id":2384855,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2022-02-19T02:55:44.000Z","date":"2018-12-12","kind":"other","acquired":true,"shares":1248,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of June 28, 2018 (as amended, the \"Merger Agreement\"), each share of common stock of Keryx Biopharmaceuticals, Inc. owned by the Reporting Person at the effective time of the transactions contemplated by the Merger Agreement was automatically converted into 0.37433 shares of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The market value of each share of the Issuer's common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018."}],"balance_after":375865,"source":{"system":"sec-edgar","filing":"0001562180-22-001654","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218022001654/primarydocument.xml","form_type":"4/A","original_submission_date":"2018-12-13"}},{"id":2612516,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-08-05T21:28:54.000Z","date":"2021-08-03","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full upon the earlier of (i) August 3, 2022, or (ii) the day before the Company's 2022 annual meeting of stockholders."}],"balance_after":7500,"derivative":{"exercise_price":4.44,"expiration_date":"2031-08-03","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001192482-21-000646","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1591467/000119248221000646/edgar.xml","form_type":"4"}},{"id":2612515,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-05T21:28:54.000Z","date":"2021-08-03","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock award vests in full upon the earlier of (i) August 3, 2022, or (ii) the day before the Company's 2022 annual meeting of stockholders."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001192482-21-000646","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591467/000119248221000646/edgar.xml","form_type":"4"}},{"id":2763442,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2021-04-02T00:32:16.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":4109,"price":3.4,"value":13970.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021."}],"balance_after":1152153,"source":{"system":"sec-edgar","filing":"0001562180-21-002540","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218021002540/primarydocument.xml","form_type":"4"}},{"id":2778763,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2021-03-18T23:17:03.000Z","date":"2021-03-16","kind":"grant","acquired":true,"shares":39520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As previously disclosed, in February 2020, the Reporting Person was granted performance-based restricted stock unit awards (\"PSUs\") pursuant to the Issuer's 2014 Incentive Plan, as amended. The PSUs vest in connection with the achievement of specified commercial and regulatory milestones. On February 25, 2021, the Company reported its financial results for the year ended December 31, 2020.  Subsequently, in accordance with the terms of the grant, the Issuer's Compensation Committee certified the achievement of a commercial milestone and, as a result, one third of the reported PSUs will vest on each of March 31, 2021, February 28, 2022 and February 28, 2023, subject to the Reporting Person's continued service with the Issuer on each vesting date."}],"balance_after":1156262,"source":{"system":"sec-edgar","filing":"0001562180-21-002354","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218021002354/primarydocument.xml","form_type":"4"}},{"id":2818979,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-03-02T21:10:39.000Z","date":"2021-02-26","kind":"grant","acquired":true,"shares":403600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":403600,"derivative":{"exercise_price":3.46,"expiration_date":"2031-02-26","underlying":"Common Stock","underlying_shares":403600},"source":{"system":"sec-edgar","filing":"0001562180-21-001787","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218021001787/primarydocument.xml","form_type":"4"}},{"id":2818978,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2021-03-02T21:10:39.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":24674,"price":3.3961,"value":83795.3714,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020."}],"balance_after":1116742,"source":{"system":"sec-edgar","filing":"0001562180-21-001787","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218021001787/primarydocument.xml","form_type":"4"}},{"id":2818977,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2021-03-02T21:10:39.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":25316,"price":3.3961,"value":85975.6676,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019."}],"balance_after":1141416,"source":{"system":"sec-edgar","filing":"0001562180-21-001787","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218021001787/primarydocument.xml","form_type":"4"}},{"id":2818976,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2021-03-02T21:10:39.000Z","date":"2021-02-26","kind":"grant","acquired":true,"shares":237400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2020 and 1,200 shares of the Issuer's common stock purchased on December 31, 2020, each under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan, and transfer of shares of the Issuer's common stock which were contributed to two grantor retained annuity trusts."}],"balance_after":1166732,"source":{"system":"sec-edgar","filing":"0001562180-21-001787","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218021001787/primarydocument.xml","form_type":"4"}},{"id":3112938,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-11T21:40:45.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests upon the earlier of (i) June 10, 2021 and (ii) the day before the Company's 2021 annual meeting of stockholders."}],"balance_after":15000,"derivative":{"exercise_price":5.21,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001192482-20-000471","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591467/000119248220000471/edgar.xml","form_type":"4"}},{"id":3237403,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to buy)","published_at":"2020-03-03T00:26:11.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":403600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter."}],"balance_after":403600,"derivative":{"exercise_price":8.87,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":403600},"source":{"system":"sec-edgar","filing":"0001562180-20-001931","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218020001931/primarydocument.xml","form_type":"4"}},{"id":3237402,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2020-03-03T00:26:11.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":237400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date."}],"balance_after":1026632,"source":{"system":"sec-edgar","filing":"0001562180-20-001931","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218020001931/primarydocument.xml","form_type":"4"}},{"id":3362717,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2019-11-21T11:32:47.000Z","date":"2019-11-20","kind":"purchase","acquired":true,"shares":50000,"price":3.44,"value":172000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The purchase reported in this Form 4 was made on the open market."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.22 to $3.65, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,500 shares of the Issuer's common stock purchased under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan on June 28, 2019."}],"balance_after":887732,"source":{"system":"sec-edgar","filing":"0001562180-19-005623","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218019005623/primarydocument.xml","form_type":"4"}},{"id":3490869,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-13T20:19:40.000Z","date":"2019-06-11","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests upon the earlier of (i) June 11, 2020, or (ii) the day before the 2020 annual meeting of stockholders of Zynerba Pharmaceuticals, Inc."}],"balance_after":15000,"derivative":{"exercise_price":13.5,"expiration_date":"2029-06-11","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001192482-19-000284","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591467/000119248219000284/edgar.xml","form_type":"4"}},{"id":3500045,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2019-06-05T20:05:54.000Z","date":"2019-06-03","kind":"exercise","acquired":false,"shares":287000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On September 16, 2013, the Issuer granted the reporting person an option to purchase 612,500 shares of the Issuer's common stock (the \"Option\") under the Issuer's Amended and Restated 2008 Equity Incentive Plan.  25% of the shares underlying the Option vested on the first anniversary of the grant date, and the remaining 75% vested in equal monthly installments over the following three years.  Prior to May 31, 2019, the reporting person exercised the Option with respect to 325,500 shares.  On May 31, 2019, the reporting person exercised the Option with respect to 287,000 shares, as reported on this Form 4."}],"balance_after":0,"derivative":{"exercise_price":0.47,"expiration_date":"2023-09-16","underlying":"Common Stock","underlying_shares":287000},"source":{"system":"sec-edgar","filing":"0001562180-19-003338","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218019003338/primarydocument.xml","form_type":"4"}},{"id":3500044,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2019-06-05T20:05:54.000Z","date":"2019-06-03","kind":"exercise","acquired":true,"shares":287000,"price":0.47,"value":134890.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects the transfer on March 15, 2019 of 65,150 shares of common stock from the reporting person's direct holdings to certain of the reporting person's trusts, the holdings for which are reported in Table I of this Form 4."}],"balance_after":836232,"source":{"system":"sec-edgar","filing":"0001562180-19-003338","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218019003338/primarydocument.xml","form_type":"4"}},{"id":3610804,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2019-03-05T21:05:48.000Z","date":"2019-02-28","kind":"grant","acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended.  25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter."}],"balance_after":350000,"derivative":{"exercise_price":7.28,"expiration_date":"2029-02-28","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001562180-19-001674","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218019001674/primarydocument.xml","form_type":"4"}},{"id":3610803,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2019-03-05T21:05:48.000Z","date":"2019-02-28","kind":"grant","acquired":true,"shares":239500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended.  One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 265 shares of the Issuer's common stock purchased under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2018."}],"balance_after":614382,"source":{"system":"sec-edgar","filing":"0001562180-19-001674","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218019001674/primarydocument.xml","form_type":"4"}},{"id":3731823,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2018-12-13T13:10:45.000Z","date":"2018-12-12","kind":"tax_withholding","acquired":false,"shares":135697,"price":8.94,"value":1213131.18,"ownership":{"direct":true},"balance_after":374617,"source":{"system":"sec-edgar","filing":"0000899243-18-030791","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000089924318030791/doc4.xml","form_type":"4"}},{"id":3835530,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-08-22T20:39:31.000Z","date":"2018-08-22","kind":"purchase","acquired":true,"shares":5000,"price":6.4306,"value":32153.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $6.31 to $6.50, inclusive. The reporting person undertakes to provide Zynerba Pharmaceuticals,\nInc., any security holder of Zynerba Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in\nfootnote 1 to this Form 4."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001192482-18-000409","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591467/000119248218000409/edgar.xml","form_type":"4"}},{"id":3868477,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2018-07-12T20:59:23.000Z","date":"2018-07-11","kind":"exercise","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On September 16, 2013, the Issuer granted the reporting person an option to purchase 612,500 shares of the Issuer's common stock (the \"Option\") under the Issuer's Amended and Restated 2008 Equity Incentive Plan.  25% of the shares underlying the Option vested on the first anniversary of the grant date, and the remaining 75% vested in equal monthly installments thereafter.  Prior to July 11, 2018, the reporting person exercised the Option with respect to 225,500 shares.  On July 11, 2018, the reporting person exercised the Option with respect to 100,000 shares, as reported on this Form 4."}],"balance_after":287000,"derivative":{"exercise_price":0.47,"expiration_date":"2023-09-16","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001562180-18-003278","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218018003278/primarydocument.xml","form_type":"4"}},{"id":3868476,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2018-07-12T20:59:23.000Z","date":"2018-07-11","kind":"exercise","acquired":true,"shares":100000,"price":0.47,"value":47000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The total amount of beneficial securities owned includes 1,500 shares of stock purchased on June 29, 2018 at $8.48 per share in connection with the Issuer's Employee Stock Purchase Plan."}],"balance_after":510314,"source":{"system":"sec-edgar","filing":"0001562180-18-003278","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218018003278/primarydocument.xml","form_type":"4"}},{"id":3901209,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-07T20:30:00.000Z","date":"2018-06-06","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests upon the earlier of (i) June 6, 2019, or (ii) the day before the 2019 annual meeting of stockholders of Zynerba Pharmaceuticals, Inc."}],"balance_after":15000,"derivative":{"exercise_price":11.3,"expiration_date":"2028-06-06","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001192482-18-000273","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591467/000119248218000273/edgar.xml","form_type":"4"}},{"id":3962881,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-04-16T20:15:55.000Z","date":"2018-04-12","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three equal installments on April 12, 2019, 2020, and 2021."}],"balance_after":35000,"derivative":{"exercise_price":9.9,"exercise_date":"2018-04-12","expiration_date":"2028-04-12","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001192482-18-000161","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591467/000119248218000161/edgar.xml","form_type":"4"}},{"id":4019288,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2018-03-02T21:15:27.000Z","date":"2018-02-28","kind":"grant","acquired":true,"shares":126300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options were granted by the Issuer pursuant to its 2014 Incentive Plan.  25% of the shares underlying this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter."}],"balance_after":126300,"derivative":{"exercise_price":14.3,"expiration_date":"2028-02-28","underlying":"Common Stock","underlying_shares":126300},"source":{"system":"sec-edgar","filing":"0001562180-18-001384","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218018001384/primarydocument.xml","form_type":"4"}},{"id":4019287,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2018-03-02T21:15:27.000Z","date":"2018-02-28","kind":"grant","acquired":true,"shares":88900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan. One hundred percent of the restricted stock units will vest on the third anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total amount of beneficial securities owned includes 1,500 shares of stock purchased on June 30, 2017 at $8.92 per share and 634 shares of stock purchased on December 31, 2017 at $12.39 per share in connection with the Issuer's Employee Stock Purchase Plan."}],"balance_after":408814,"source":{"system":"sec-edgar","filing":"0001562180-18-001384","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218018001384/primarydocument.xml","form_type":"4"}},{"id":4276399,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2017-06-20T16:09:29.000Z","date":"2017-06-09","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The 30,000 stock options vest as to one-third on each of June 9, 2018, June 9, 2019 and June 9, 2020."}],"balance_after":30000,"derivative":{"exercise_price":6.56,"exercise_date":"2018-06-09","expiration_date":"2027-06-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-17-016762","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000089924317016762/doc4.xml","form_type":"4"}},{"id":4276398,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-20T16:09:29.000Z","date":"2017-06-09","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The 10,000 shares are restricted common stock, with one-third of the 10,000 shares vesting on each of June 9, 2018, June 9, 2019 and June 9, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 16,666 shares of restricted stock."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0000899243-17-016762","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000089924317016762/doc4.xml","form_type":"4"}},{"id":4427185,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to buy)","published_at":"2017-02-23T21:02:00.000Z","date":"2017-02-21","kind":"grant","acquired":true,"shares":190000,"price":10.14,"value":1926600.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares underlying this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter."}],"balance_after":190000,"derivative":{"exercise_price":0,"expiration_date":"2027-02-21","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0001562180-17-000879","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218017000879/primarydocument.xml","form_type":"4"}},{"id":4427184,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2017-02-23T21:02:00.000Z","date":"2017-02-21","kind":"grant","acquired":true,"shares":119500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan. One hundred percent of the restricted stock units will vest on the third anniversary of the Grant Date."}],"balance_after":317780,"source":{"system":"sec-edgar","filing":"0001562180-17-000879","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218017000879/primarydocument.xml","form_type":"4"}},{"id":4456774,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2017-02-10T21:04:08.000Z","date":"2016-07-28","kind":"gift","acquired":true,"shares":58400,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"GRAT - Spouse"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Of the shares tranferred by the reporting person on July 28, 2016, 58,400 were contributed to the Dorothy Butler 2016 GRAT, of which the reporting person's wife serves as trustee."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Of the shares tranferred by the reporting person on July 28, 2016, 58,400 were contributed to the Dorothy Butler 2016 GRAT, of which the reporting person's wife serves as trustee."}],"balance_after":58400,"source":{"system":"sec-edgar","filing":"0001562180-17-000613","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218017000613/primarydocument.xml","form_type":"5"}},{"id":4456773,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2017-02-10T21:04:08.000Z","date":"2016-07-28","kind":"gift","acquired":false,"shares":116800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2016, the reporting person made the following transfers for estate planning purposes: 58,400 shares were transferred to the Dorothy Butler 2016 GRAT, 29,200 shares were transferred to the Dorothy Butler 2016 Irrevocable Trust, and 29,200 shares were transferred to the John P. Butler 2016 Irrevocable Trust."}],"balance_after":198280,"source":{"system":"sec-edgar","filing":"0001562180-17-000613","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218017000613/primarydocument.xml","form_type":"5"}},{"id":4483942,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to buy)","published_at":"2017-01-23T21:10:14.000Z","date":"2017-01-19","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of this option vested on September 16, 2014.  The remaining shares vest in equal monthly installments through September 1, 2017."}],"balance_after":387000,"derivative":{"exercise_price":0.47,"expiration_date":"2023-09-16","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001562180-17-000318","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218017000318/primarydocument.xml","form_type":"4"}},{"id":4483941,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":24946,"kind":"person","name":"Butler John P.","position":1,"cik":"0001591467","reported_name":"Butler John P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2017-01-23T21:10:14.000Z","date":"2017-01-19","kind":"exercise","acquired":true,"shares":20000,"price":0.47,"value":9400.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction represents the acquisition of common stock as a result of the exercise and hold of derivative securities reported in Table II."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total amount of beneficial securities includes 1,500 shares of stock purchased on June 30, 2016 at $6.35 per share and 807 shares of stock purchased on December 30, 2016 at $6.48 per shares in connection with the Issuer's Employee Stock Purchase Plan."}],"balance_after":373480,"source":{"system":"sec-edgar","filing":"0001562180-17-000318","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218017000318/primarydocument.xml","form_type":"4"}}]}